Ophthalmic Examination of Dizygotic Twins in Queensland
Principal Investigator
David Mackey, MD
Royal Victorian Ear and Eye Hospital
East Melbourne, Australia
About the Research Project
Program
Award Type
Standard
Award Amount
$80,000
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
G2005002
Summary
Glaucoma is thought to have a major genetic component. Several genes have been identified, but so far these only accounts for 5% of glaucoma cases. Twin studies are an important tool for determining the relative contribution of genes or environment in any measure. If there is very little genetic component, then identical twins will vary as much as non identical twins. Dr. Mackey will analyze pressure, refraction, optic nerve, corneal thickness and many other measures in his study, and then compare all the numerical measurements of the twins with their DNA markers to discover where similar twins consistently have similar DNA markers. Discovering the genes that cause glaucoma will enable other family members to be tested and predict who is at high risk or low risk of developing glaucoma. This will allow better early screening for glaucoma and potentially lead to the development of new treatments.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego